Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Targeted Cancer Therapies

Targeted Cancer Therapies

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The DBD-α4 helix of EWSR1::FLI1 is required for GGAA microsatellite binding that underlies genome regulation in Ewing sarcoma.

eLife·2026

Same author

A scalable, multi-resolution consensus clustering approach for prioritizing robust signals from high-throughput screens.

Briefings in bioinformatics·2026

Same author

Identifying therapeutic targets in low-grade serous ovarian carcinomas with no specific molecular profile.

The Journal of pathology·2026

Same author

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on <i>KRAS/NF1</i> Mutational Status.

International journal of molecular sciences·2026

Same author

Assessment of candidate high-grade serous ovarian carcinoma predisposition genes through integrated germline and tumour sequencing.

NPJ genomic medicine·2025

Same author

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma.

Scientific data·2024

Search research articles

Related Experiment Video

Updated: Mar 15, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Recent advances in targeted therapy for Ewing sarcoma.

Kathleen I Pishas¹, Stephen L Lessnick²

¹Cancer Therapeutics Laboratory, Center for Personalized Cancer Medicine, Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia; Center for Childhood Cancer and Blood Disorders, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.

|September 17, 2016

Summary

This summary is machine-generated.

Ewing sarcoma is a deadly bone cancer in children. New therapies targeting the EWS/ETS fusion are crucial for improving survival in relapsed and metastatic cases.

Keywords:

EWS/FLI Ewing sarcoma ganitumab sarcoma

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Related Experiment Videos

Last Updated: Mar 15, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Area of Science:

Oncology
Pediatric Oncology
Cancer Genetics

Background:

Ewing sarcoma is an aggressive bone cancer predominantly affecting young individuals.
Current multi-modal therapies have limited efficacy in relapsed and metastatic cases, with a 70% mortality rate.
The lack of targetable mutations necessitates novel therapeutic approaches.

Purpose of the Study:

To highlight the urgent need for novel therapeutic strategies in Ewing sarcoma.
To emphasize the EWS/ETS fusion as a key therapeutic target.
To underscore the importance of translating research into clinical practice for this disease.

Main Methods:

Review of current therapeutic strategies for Ewing sarcoma.
Analysis of the genetic landscape of Ewing sarcoma, focusing on the EWS/ETS fusion.
Discussion of the challenges and opportunities in targeting the EWS/ETS fusion.

Main Results:

Ewing sarcoma exhibits a poor prognosis in relapsed and metastatic settings.
Targetable signal transduction pathways are infrequent in Ewing sarcoma.
The EWS/ETS fusion is identified as the master regulator and a critical therapeutic target.

Conclusions:

There is a critical need for innovative treatments for relapsed and metastatic Ewing sarcoma.
Targeting the EWS/ETS fusion presents a promising strategy for Ewing sarcoma therapy.
Translational research is essential to improve survival outcomes for young patients with this rare cancer.